Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
brilaroxazine
Class :
Atypical antipsychotic
Brand Name :
N/A
Synonyms :
brilaroxazine
Class :
Atypical antipsychotic
Dosage Forms & StrengthsÂ
N/AÂ
Brilaroxazine (FDA approval pending) is an investigational drug which is under development and is in phase III clinical trials
Not suggested Â
Refer to adult dosingÂ
Actions and SpectrumÂ
Brilaroxazine involves modulation of serotonin and dopamine receptors in the brain. It acts as a partial agonist at serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors.
Frequency not defined Â
None
Black Box WarningÂ
NoneÂ
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy consideration:Â
Pregnancy category: N/AÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology Â
Brilaroxazine is a serotonin-dopamine activity modulator. Its pharmacological effects involve interactions with serotonin and dopamine receptors in the brain.Â
PharmacodynamicsÂ
Brilaroxazine acts as a partial agonist at dopamine D2 receptors. Modulation of D2 receptors is relevant to the treatment of schizophrenia, as dopamine dysregulation is implicated in these conditions.Â
PharmacokineticsÂ
AbsorptionÂ
Brilaroxazine is administered orally and is absorbed into the bloodstream.Â
DistributionÂ
Brilaroxazine is distributed throughout the body.Â
MetabolismÂ
Brilaroxazine undergoes metabolism in the liver. Â
ExcretionÂ
Brilaroxazine is excreted through the feces.
AdministrationÂ
Brilaroxazine is under investigation, and it is taken orally.
Patient information leafletÂ
Generic Name: brilaroxazineÂ
Why do we use brilaroxazine?Â
Brilaroxazine (FDA approval pending) was being investigated for its potential as an antipsychotic in the treatment of schizophrenia and schizoaffective disorder.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
